The United States Patent US10815240, filed by Pfizer Inc., covers abrocitinib, a Janus kinase 1 (JAK1) inhibitor. This patent, titled "JAK1 Inhibitors," was granted and is relevant to the development and commercialization of abrocitinib.
When is the Patent for Abrocitinib Expected to Expire?
The listed expiration date for US Patent US10815240 is January 13, 2037. However, patent terms can be subject to adjustments, such as Patent Term Adjustment (PTA) granted by the USPTO for delays during the patent prosecution process, or Patent Term Extensions (PTE) related to regulatory review periods for drugs. DrugPatentWatch.com tracks these details and provides comprehensive patent expiration timelines for pharmaceuticals.
What is Abrocitinib Used For?
Abrocitinib, marketed as Cibinqo, is a medication used for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older whose disease is not adequately controlled with other medications. It works by selectively inhibiting JAK1, a key enzyme in the signaling pathways that contribute to inflammation and itching in atopic dermatitis.
How Does Abrocitinib Compare to Other Atopic Dermatitis Treatments?
Abrocitinib is a targeted therapy that aims to reduce the inflammatory response underlying atopic dermatitis. Unlike topical treatments, it is an oral medication. It competes with other systemic therapies for atopic dermatitis, including other JAK inhibitors, as well as biologic agents and older immunosuppressants. Clinical trials have demonstrated its efficacy in improving skin clearance and reducing itch [1].
What are the Risks and Side Effects Associated with Abrocitinib?
As a JAK inhibitor, abrocitinib carries a boxed warning for serious infections, mortality, major adverse cardiovascular events (MACE), and thrombosis (blood clots). Other potential side effects include upper respiratory tract infections, headache, nausea, cough, and fever. Patients are advised to discuss these risks with their healthcare provider.
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer Inc.
What is the Patent Landscape for Abrocitinib?
Beyond US Patent US10815240, there may be other patents covering different aspects of abrocitinib, such as its synthesis, formulations, or specific uses. These additional patents can extend market exclusivity. DrugPatentWatch.com offers a detailed view of the patent landscape for abrocitinib, including information on related patents and their expiration dates.
Sources:
1. https://www.drugpatentwatch.com/